FASN’s role in lipid synthesis is well established, and the FASN inhibitor TVB-2640 decreases hepatic DNL in healthy volunteers with characteristics of metabolic syndrome30 and liver fat in NASH patients24. This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.